MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 10-29-2024
10x Genomics Income Statement 2011-2025 | TXG
Annual Income Statement 10x Genomics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
5.64 B | 5.98 B | 8.99 B | 18 B | 3.66 B | - | 1.06 B | - | - | - | - | - | - |
Shares |
117 M | 114 M | 110 M | 101 M | 39.1 M | - | 82.9 M | - | - | - | - | - | - |
Historical Prices |
48.2 | 52.5 | 81.5 | 178 | 79.7 | - | - | - | - | - | - | - | - |
Net Income |
-255 M | -166 M | -58.2 M | -543 M | -31.3 M | -112 M | -18.8 M | - | - | - | - | - | - |
Revenue |
619 M | 516 M | 490 M | 299 M | 246 M | 146 M | 71.1 M | - | - | - | - | - | - |
Cost of Revenue |
209 M | 120 M | 74.1 M | 58.5 M | 61 M | 28.7 M | 10.6 M | - | - | - | - | - | - |
Gross Profit |
409 M | 396 M | 416 M | 240 M | 185 M | 118 M | 60.5 M | - | - | - | - | - | - |
Operating Income |
-265 M | -168 M | -52.3 M | -534 M | -30.6 M | -111 M | -18.4 M | - | - | - | - | - | - |
Interest Expense |
33 K | 476 K | 866 K | 1.68 M | 3.08 M | 2.41 M | 811 K | - | - | - | - | - | - |
EBITDA |
-230 M | -143 M | -31.1 M | -520 M | -23.5 M | -44.5 M | -14.1 M | - | - | - | - | - | - |
Operating Expenses |
675 M | 564 M | 469 M | 775 M | 215 M | 166 M | 78.9 M | - | - | - | - | - | - |
General and Administrative Expenses |
343 M | 298 M | 258 M | 202 M | 131 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement 10x Genomics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
121 M | 120 M | 119 M | 118 M | 117 M | 116 M | - | - | 114 M | 113 M | 113 M | 111 M | 110 M | 109 M | 108 M | 101 M | 99 M | 96.8 M | 96.2 M | 29.2 M | 15.6 M | 14.8 M | 14.5 M | 13.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-35.8 M | -37.9 M | -59.9 M | -93 M | -62.4 M | -50.7 M | - | - | -64.5 M | -42.4 M | - | -17.2 M | -11.1 M | -11.6 M | - | -65.8 M | -40.2 M | -21.1 M | -7.13 M | -9.6 M | -10.9 M | -3.64 M | -75.5 M | -15.3 M | -5.92 M | -15.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
152 M | 153 M | 141 M | 154 M | 147 M | 134 M | - | - | 115 M | 114 M | - | 125 M | 116 M | 106 M | - | 71.8 M | 42.9 M | 71.9 M | 75.3 M | 61.2 M | 55.8 M | 53.6 M | 50.6 M | 36.6 M | 31.7 M | 27.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
45.3 M | 48.9 M | 48.1 M | 58.1 M | 47.2 M | 35.9 M | - | - | 27.7 M | 25.5 M | - | 24.5 M | 4.92 M | 17.1 M | - | 14.4 M | 10.1 M | 15.1 M | - | 15.5 M | 15 M | 14 M | - | 5.24 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
106 M | 104 M | 92.9 M | 95.5 M | 99.6 M | 98.4 M | - | - | 86.9 M | 89 M | - | 101 M | 111 M | 88.8 M | - | 57.4 M | 32.9 M | 56.8 M | 58.7 M | 45.7 M | 40.8 M | 39.6 M | 35.7 M | 31.4 M | 27.2 M | 23.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-41.5 M | -41.7 M | -61.5 M | -94.8 M | -63.4 M | -52 M | - | - | -63.1 M | -41.7 M | - | -15.9 M | -10.3 M | -10.2 M | - | -65.3 M | -39.4 M | -19.9 M | - | -9.1 M | -10.4 M | -3.04 M | - | -14.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
2.08 M | -56 K | 1 K | -1.25 M | -1.5 M | 19 K | - | - | 109 K | 128 K | - | 219 K | 209 K | 221 K | - | 397 K | 306 K | 662 K | - | 708 K | 695 K | 684 K | - | 659 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
- | - | -52.3 M | - | - | -45.5 M | - | - | -50.4 M | -35.5 M | - | -15.9 M | -687 K | -5.46 M | - | -55.2 M | -32.9 M | -16.7 M | - | -4.88 M | -8.18 M | -2 M | - | -11.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
148 M | 146 M | 154 M | 190 M | 163 M | 150 M | - | - | 150 M | 131 M | - | 117 M | 121 M | 99 M | - | 123 M | 72.3 M | 76.7 M | - | 54.8 M | 51.2 M | 42.6 M | - | 46.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
81.7 M | 83 M | 85.8 M | 82.4 M | 91.5 M | 83.3 M | - | - | 79.3 M | 66.7 M | - | 62.1 M | 68.7 M | 56.9 M | - | 51.5 M | 44.4 M | 50.4 M | - | 32.6 M | 32.6 M | 26.9 M | - | 19.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company 10x Genomics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B |  USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Evolent Health
EVH
|
$ 4.11 | -0.48 % | $ 385 M | USA |
 |
Health Catalyst
HCAT
|
$ 2.34 | -4.82 % | $ 141 M | USA |
 |
HealthStream
HSTM
|
$ 24.4 | 0.95 % | $ 741 M | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
HealthEquity
HQY
|
$ 96.06 | -0.75 % | $ 8.22 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 13.18 | -1.35 % | $ 226 M | USA |
 |
American Well Corporation
AMWL
|
$ 4.68 | 1.3 % | $ 70.2 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
Progyny
PGNY
|
$ 26.39 | -1.2 % | $ 2.26 B | USA |
 |
Premier
PINC
|
$ 28.26 | - | $ 2.33 B | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 2.72 | -3.72 % | $ 1.05 B | USA |
 |
Schrödinger
SDGR
|
$ 18.41 | 1.99 % | $ 1.34 B | USA |
 |
Omnicell
OMCL
|
$ 43.31 | -1.25 % | $ 1.99 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
Phreesia
PHR
|
$ 16.68 | 2.71 % | $ 910 M | USA |
 |
So-Young International
SY
|
$ 2.92 | -5.66 % | $ 232 M |  China |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Veeva Systems
VEEV
|
$ 219.17 | -1.81 % | $ 35.2 B | USA |
 |
Zhongchao
ZCMD
|
$ 0.58 | -3.18 % | $ 3.02 M | China |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
Teladoc Health
TDOC
|
$ 7.36 | -2.65 % | $ 1.26 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
SCWorx Corp.
WORX
|
$ 0.21 | 5.86 % | $ 306 K | USA |